BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

What happened: BridgeBio Pharma (Nasdaq: BBIO) will present additional evidence from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 at the ASBMR 2026 Annual Meeting in Boston, October 9-12, 2026. Key numbers: Meeting dates October 9-12, Why it matters: The presentations cover encaleret effects on patient-reported outcomes and bone turnover, plus a proband-initiated cascade genetic testing model with the HypoPARAthyroidism Association. A separate poster supports the infigratinib safety profile seen in children with achondroplasia in the PROPEL program.

BridgeBio Pharma (Nasdaq: BBIO) will present additional evidence from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 at the ASBMR 2026 Annual Meeting in Boston, October 9-12, 2026.

The presentations cover encaleret effects on patient-reported outcomes and bone turnover, plus a proband-initiated cascade genetic testing model with the HypoPARAthyroidism Association. A separate poster supports the infigratinib safety profile seen in children with achondroplasia in the PROPEL program.